Key takeaways
Glyxambi (empagliflozin/linagliptin) and Jardiance (empagliflozin) are both used to treat Type 2 diabetes, but they have some key differences. Glyxambi is a combination of two medications: empagliflozin, an SGLT2 inhibitor, and linagliptin, a DPP-4 inhibitor. Jardiance, on the other hand, contains only empagliflozin. Glyxambi can lower the risk of death from heart disease in people with Type 2 diabetes and heart disease, while Jardiance can also lower the risk of hospitalization and death in adults with heart failure or chronic kidney disease. Glyxambi is taken once daily in the morning, and Jardiance is also taken once daily, but it can be taken at any time of day. Both medications can cause urinary tract infections and yeast infections. Additionally, Jardiance is currently only available as a brand-name medication, with generics expected in 2025, while Glyxambi does not have a generic form available.
